Department of Medicine, Division of Cardiology (T.J.B., E.D., M.S.G., Y.O., E.A.F.), New York University School of Medicine.
Haematopoiesis and Leukocyte Biology, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (A.J.M.).
Circulation. 2019 Oct;140(14):1170-1184. doi: 10.1161/CIRCULATIONAHA.119.039476. Epub 2019 Sep 30.
Despite robust cholesterol lowering, cardiovascular disease risk remains increased in patients with diabetes mellitus. Consistent with this, diabetes mellitus impairs atherosclerosis regression after cholesterol lowering in humans and mice. In mice, this is attributed in part to hyperglycemia-induced monocytosis, which increases monocyte entry into plaques despite cholesterol lowering. In addition, diabetes mellitus skews plaque macrophages toward an atherogenic inflammatory M1 phenotype instead of toward the atherosclerosis-resolving M2 state typical with cholesterol lowering. Functional high-density lipoprotein (HDL), typically low in patients with diabetes mellitus, reduces monocyte precursor proliferation in murine bone marrow and has anti-inflammatory effects on human and murine macrophages. Our study aimed to test whether raising functional HDL levels in diabetic mice prevents monocytosis, reduces the quantity and inflammation of plaque macrophages, and enhances atherosclerosis regression after cholesterol lowering.
Aortic arches containing plaques developed in mice were transplanted into either wild-type, diabetic wild-type, or diabetic mice transgenic for human apolipoprotein AI, which have elevated functional HDL. Recipient mice all had low levels of low-density lipoprotein cholesterol to promote plaque regression. After 2 weeks, plaques in recipient mouse aortic grafts were examined.
Diabetic wild-type mice had impaired atherosclerosis regression, which was normalized by raising HDL levels. This benefit was linked to suppressed hyperglycemia-driven myelopoiesis, monocytosis, and neutrophilia. Increased HDL improved cholesterol efflux from bone marrow progenitors, suppressing their proliferation and monocyte and neutrophil production capacity. In addition to reducing circulating monocytes available for recruitment into plaques, in the diabetic milieu, HDL suppressed the general recruitability of monocytes to inflammatory sites and promoted plaque macrophage polarization to the M2, atherosclerosis-resolving state. There was also a decrease in plaque neutrophil extracellular traps, which are atherogenic and increased by diabetes mellitus.
Raising apolipoprotein AI and functional levels of HDL promotes multiple favorable changes in the production of monocytes and neutrophils and in the inflammatory environment of atherosclerotic plaques of diabetic mice after cholesterol lowering and may represent a novel approach to reduce cardiovascular disease risk in people with diabetes mellitus.
尽管胆固醇水平显著降低,糖尿病患者的心血管疾病风险仍然增加。与此一致的是,糖尿病会损害人类和小鼠胆固醇降低后的动脉粥样硬化消退。在小鼠中,这部分归因于高血糖诱导的单核细胞增多症,尽管胆固醇降低,单核细胞仍会增加进入斑块的数量。此外,糖尿病会使斑块中的巨噬细胞向促动脉粥样硬化炎症的 M1 表型倾斜,而不是向胆固醇降低时典型的动脉粥样硬化消退的 M2 状态倾斜。功能性高密度脂蛋白(HDL)在糖尿病患者中通常较低,它可减少小鼠骨髓中单核细胞前体的增殖,并对人类和小鼠巨噬细胞具有抗炎作用。我们的研究旨在测试在糖尿病小鼠中升高功能性 HDL 水平是否可防止单核细胞增多症、减少斑块巨噬细胞的数量和炎症,并增强胆固醇降低后的动脉粥样硬化消退。
将在 小鼠中形成的含有斑块的主动脉弓移植到野生型、糖尿病野生型或转人载脂蛋白 AI 的糖尿病小鼠中,后者具有升高的功能性 HDL。所有受体小鼠的低密度脂蛋白胆固醇水平均较低,以促进斑块消退。2 周后,检查受体小鼠主动脉移植物中的斑块。
糖尿病野生型小鼠的动脉粥样硬化消退受损,升高 HDL 水平可使其恢复正常。这种益处与抑制高血糖驱动的骨髓生成、单核细胞增多症和嗜中性粒细胞增多有关。增加 HDL 可促进骨髓祖细胞的胆固醇流出,抑制其增殖和单核细胞及嗜中性粒细胞的产生能力。除了减少循环单核细胞可用于募集到斑块中外,在糖尿病环境中,HDL 还抑制了单核细胞向炎症部位的一般募集能力,并促进斑块巨噬细胞向 M2、动脉粥样硬化消退状态极化。斑块中性粒细胞细胞外陷阱(一种促动脉粥样硬化的物质,会被糖尿病增加)也有所减少。
升高载脂蛋白 AI 和功能性 HDL 水平可促进胆固醇降低后糖尿病小鼠单核细胞和嗜中性粒细胞的产生以及动脉粥样硬化斑块炎症环境的多种有利变化,可能代表降低糖尿病患者心血管疾病风险的新方法。